类风湿关节炎患者自报疼痛相关健康结局的轨迹及其对用药的纵向影响:基于澳大利亚风湿病学协会数据库(ARAD)的前瞻性队列分析
基于澳大利亚风湿病学协会数据库988例类风湿关节炎患者(71%女性,平均年龄54岁,平均病程2.3年),采用潜变量离散混合模型识别5项自报疼痛相关健康结局的15年多轨迹,发现4个大致等大的疼痛/健康状态组;较差组更常见女性、肥胖、吸烟、社会经济指标和合并症,且生物制剂调整及非TNF抑制剂、阿片类、泼尼松龙和非甾体抗炎药使用更多。
要点
- 988例类风湿关节炎患者中识别出4个大致等大的疼痛/健康状态轨迹组,从「较好」到「较差」,组内随时间变化相对较小。
- 较差疼痛/健康状态的重要决定因素包括女性、肥胖、吸烟、社会经济指标和合并症。
- 随访期间各组生物制剂使用相似,但较差组生物制剂调整更多、非TNF抑制剂使用倾向更高,阿片类、泼尼松龙和非甾体抗炎药使用也更多。
核心结论
- 在缺乏疾病活动度信息的情况下,该类风湿关节炎队列从起点及整个病程中均可见疼痛/健康状态不同的轨迹。
- 疼痛/健康状态较差者生物制剂调整更多,抗炎药、阿片类和泼尼松龙使用更多,反映类风湿关节炎持续性疼痛的不良生活体验。
研究设计与样本
- 前瞻性队列分析,纳入澳大利亚风湿病学协会数据库988例类风湿关节炎参与者(71%女性,平均年龄54岁,平均病程2.3年),随访15年。
- 采用潜变量离散混合模型识别5项自报疼痛相关健康结局(健康评估问卷残疾指数、疼痛视觉模拟评分、关节炎视觉模拟评分、总体健康视觉模拟评分和评估生活质量效用指数)的多轨迹。
- 采用随机效应模型确定与药物使用及生物制剂调整的关联。
主要发现
- 识别出4个大致等大的疼痛/健康状态组,范围从「较好」到「较差」,组内随时间变化相对较小。
- 较差疼痛/健康状态的重要决定因素包括女性、肥胖、吸烟、社会经济指标和合并症。
- 随访期间各组生物制剂使用相似,但较差疼痛/健康状态组生物制剂调整更多(plinear<0.001),非TNF抑制剂使用倾向更高(plinear<0.001)。
- 较差疼痛/健康状态组阿片类、泼尼松龙和非甾体抗炎药使用更多。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine distinct trajectories of self-reported pain-related health status in rheumatoid arthritis (RA), their relationship with sociodemographic factors and medication use. METHODS: 988 Australian Rheumatology Association Database participants with RA (71% female, mean age 54 years, mean disease duration 2.3 years) were included. Distinct multi-trajectories over 15-year follow-up for five different self-reported pain-related health outcome measures (Health Assessment Questionnaire Disability Index, visual analogue scores for pain, arthritis, global health and the Assessment of Quality of Life utility index) were identified using latent variable discrete mixture modelling. Random effects models were used to determine associations with medication use and biologic therapy modification during follow-up. RESULTS: Four, approximately equally sized, pain/health status groups were identified, ranging from 'better' to 'poorer', within which changes over time were relatively small. Important determinants of those with poorer pain/health status included female gender, obesity, smoking, socioeconomic indicators and comorbidities. While biologic therapy use was similar between groups during follow-up, biologic therapy modifications (plinear<0.001) and greater tendency of non-tumour necrosis factor inhibitor use (plinear<0.001) were observed in those with poorer pain/health status. Similarly, greater use of opioids, prednisolone and non-steroidal anti-inflammatory drugs was seen in those with poorer pain/health status. CONCLUSION: In the absence of disease activity information, distinct trajectories of varying pain/health status were seen from the outset and throughout the disease course in this RA cohort. More biologic therapy modifications and greater use in anti-inflammatories, opioids and prednisolone were seen in those with poorer pain/health status, reflecting undesirable lived experience of persistent pain in RA.
引用
- Pisaniello HL, Lester S, Russell O, et al. Trajectories of self-reported pain-related health outcomes and longitudinal effects on medication use in rheumatoid arthritis: a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD). RMD Open. 2023. PMID: 37507204. doi:10.1136/rmdopen-2022-002962
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。